Kenta Kasahara

Kenta Kasahara

Auto-generated profile, based on publicly available information

Kenta Kasahara

Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2022 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
KKKenta Kasahara
Kenta Kasahara
KKKenji Katsumata
Kenji Katsumata
ASAkira Saito
Akira Saito
TITetsuo Ishizaki
Tetsuo Ishizaki
MEMasanobu Enomoto
Masanobu Enomoto
ATAkihiko Tsuchida
Akihiko Tsuchida


8 July 2022 in Medicine
Verified
Journal Article
Open access
JMJunichi Mazaki
Junichi Mazaki
KKKenji Katsumata
Kenji Katsumata
TITetsuo Ishizaki
Tetsuo Ishizaki
NFNoritoshi Fukushima
Noritoshi Fukushima
RURyutaro Udo
Ryutaro Udo
ATAkihiko Tsuchida
Akihiko Tsuchida
Anastomotic leakage (AL) after colorectal surgery is a serious complication. This study aimed to evaluate the effectiveness of the EEA™ circular stapler, a new triple-row circular stapler (TCS), relative to a conventional, double-row circular stapler (DCS). A total of 285 patients who underwent anastomosis with the double stapling technique at the Tokyo Medical University Hospital between 2017 and 2021 were included in this nonrandomized clinical trial with historical controls using a propensity score (PS) analysis. The primary endpoint was the risk of AL. We performed a 1:2 PS matching analysis. Before case matching, AL occurred in 15 (7.4%) and 2 (2.4%) patients in the DCS and TCS groups, respectively, with no significant difference (P = .17). After case matching, AL occurred in 13 patients (11.6%) and 1 patient (1.8%) in the DCS and TCS groups, respectively, revealing a significant difference (P = .04). Cox models were created by applying PS to adjust for group differences via regression adjustment. Odds ratios for AL in the DCS group versus the TCS group were 0.31 (95% confidence interval [CI]: 0.07–1.38) in the entire cohort, 0.15 (95% CI: 0.02–0.64) in the regression adjustment cohort, and 0.14 (95% CI: 0.02–1.09) in the 1:2 PS-matched cohort. PS analysis of clinical data suggested that the use of TCS contributes to a reduced risk of AL after colorectal anastomosis CTwith the double stapling technique.

2 September 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TITetsuo Ishizaki
Tetsuo Ishizaki
Masahiro SugimotoMasahiro Sugimoto
Masahiro Sugimoto
YKYu Kuboyama
Yu Kuboyama
JMJunichi Mazaki
Junichi Mazaki
KKKenta Kasahara
Kenta Kasahara
YNYuichi Nagakawa
Yuichi Nagakawa
Background/Objectives: The objective of this study was to investigate the metabolomic profiles of patients with colorectal cancer (CRC) across various stages of the disease. Methods: The plasma samples were obtained from 255 subjects, including patients with CRC in stages I-IV, polyps, and controls. We employed capillary electrophoresis time-of-flight mass spectrometry and liquid chromatography triple quadrupole mass spectrometry to analyze hydrophilic metabolites comprehensively. The data were randomly divided into two groups, and consistent differences observed in both groups were analyzed. Results: Acetylated polyamines, such as N1-acetylspermine and N1, N12-diacetylspermine, consistently showed elevated concentrations in stage IV compared to stages I-III. Non-acetylated polyamines, including spermine and spermidine, exhibited increasing trends from polyp to stage IV. Other metabolites, such as histidine and o-acetylcarnitine, showed decreasing trends across stages. While acetylated polyamines have been reported as CRC detection markers, our findings suggest that they also possess diagnostic potential for distinguishing stage IV from other stages. Conclusions: This study showed stage-specific changes in metabolic profiles, including polyamines, of colorectal cancer.

10 January 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
TSToru Sakurai
Toru Sakurai
KKKenji Katsumata
Kenji Katsumata
RURyutaro Udo
Ryutaro Udo
TTTomoya Tago
Tomoya Tago
KKKenta Kasahara
Kenta Kasahara
ATAkihiko Tsuchida
Akihiko Tsuchida
This study aimed to validate and reanalyze urinary biomarkers for detecting colorectal cancers (CRCs). We previously conducted urinary metabolomic analyses using capillary electrophoresis-mass spectrometry and found a significant difference in various metabolites, especially polyamines, between patients with CRC and healthy controls (HC). We analyzed additional samples and confirmed consistency between the newly and previously analyzed data. In total, we included 36 HC, 34 adenoma (AD), and 214 CRC samples, which were used for subsequent analyses. Among the 132 quantified metabolites, 16 exhibited consistent differences in both datasets, which included polyamines, etc. Pathway analyses of the integrated data revealed significant differences in many metabolites, such as glutamine, and metabolites of the TCA (tricarboxylic acid cycle) and urea cycles. The discrimination ability of the combination of multiple metabolites among the three groups was evaluated, which yielded higher sensitivity than tumor markers. The Mann–Whitney test was employed to evaluate the prognosis predictivity of the assessed metabolites and the difference between the patients with or without recurrence, which yielded 16 significantly different metabolites. Among these 16 metabolites, 11 presented significant prognosis predictivity. These data indicated the potential of metabolite-based discrimination of patients with CRC and AD from HC and prognosis predictivity of the monitored metabolites.

8 July 2021 in Indian Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
KKKenta Kasahara
Kenta Kasahara
TITetsuo Ishizaki
Tetsuo Ishizaki
MEMasanobu Enomoto
Masanobu Enomoto
JMJunichi Mazaki
Junichi Mazaki
NONaoto Okazaki
Naoto Okazaki
ATAkihiko Tsuchida
Akihiko Tsuchida
Lymphocyte-to-monocyte ratio (LMR) has been reported as a biomarker for predicting the prognosis of colorectal cancer. However, the clinical usefulness of LMR requires detailed research, which can contribute to better therapeutic strategies. A cohort of 554 patients with resectable advanced colon cancer in our institution was analyzed retrospectively. An analysis of stages II and III resectable advanced colon cancer was performed. LMR was useful for predicting overall survival (OS) and relapse-free survival (RFS). The ROC curve revealed an LMR value of 2.77 as a cutoff for OS. A high LMR was an independent prognostic factor and was associated with a high hazard ratio (HR) in all cases for OS (HR = 0.530, 95% confidence interval (CI) = 0.334–0.842, p = 0.007). A high LMR was not an independent prognostic factor in stage II cases but was a predictor with the strongest association with prognosis in patients with stage III cases for OS (HR = 0.383, 95% CI = 0.160–0.915, p = 0.031). LMR is a strong predictor of prognosis in patients with stage III colon cancer and may be useful in postoperative treatment options.